|
US2020399363A1
|
|
Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
|
|
TW202038958A
|
|
Cd70 combination therapy
|
|
WO2020121282A1
|
|
Antibodies to human complement factor c2b and methods of use
|
|
GB201917701D0
|
|
CD70 Combination therapy
|
|
GB201911007D0
|
|
CD70 combination therapy
|
|
SG11202011849VA
|
|
Compositions and methods for treating immune thrombocytopenia
|
|
GB201907153D0
|
|
Methods of treating neuropathy
|
|
AU2019250689A1
|
|
Galectin-10 antibodies
|
|
GB201905150D0
|
|
Ant-ige antibodies
|
|
GB201901648D0
|
|
Galectin-10 antibodies
|
|
CA3079793A1
|
|
Bispecific antigen binding construct
|
|
GB201820582D0
|
|
CD70 combination therapy
|
|
CA3081144A1
|
|
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
GB201806099D0
|
|
Galectin-10 Antibodies
|
|
GB201802487D0
|
|
Cytokine combination therapy
|
|
GB201800649D0
|
|
CD70 Combination Therapy
|
|
WO2018083122A1
|
|
Human fcrn binding antibody for use in treatment of antibody mediated disease
|
|
EP3526330A1
|
|
Triple vector for expressing antibody molecules in full therapeutic format
|
|
GB201709677D0
|
|
Treatment for acute myeloid leukaemia
|
|
GB201707561D0
|
|
GARP-TGF-beta antibodies
|
